



## 35 **ABSTRACT**

36

37 Li-Fraumeni syndrome (LFS) is a heterogeneous predisposition to a broad spectrum  
38 of cancers caused by pathogenic *TP53* germline variants. We have used a clustering  
39 approach to assign missense variants to functional classes with distinct quantitative  
40 and qualitative features based on transcriptional activity in yeast assays. Genotype-  
41 phenotype correlations were analyzed using the germline *TP53* mutation database (n  
42 = 3,446) and validated in three LFS clinical cohorts (n= 821). Carriers of class A  
43 variants recapitulated all traits of fully penetrant LFS (median age at first diagnosis =  
44 28 years). Class B carriers showed a less penetrant form (median = 33 years,  $p < 0.05$ )  
45 dominated by adrenocortical and breast cancers. Class C or D carriers had attenuated  
46 phenotypes (median = 41 years,  $p < 0.001$ ) with typical LFS cancers in C and mostly  
47 non-LFS cancers in D. This new classification provides insight into structural/functional  
48 features causing pathogenicity.

49

## 50 **INTRODUCTION**

51

52 Li-Fraumeni syndrome (LFS; Mendelian Inheritance in Man [MIM] #151623) is an  
53 autosomal dominant cancer predisposition syndrome associated with a high lifetime  
54 risk of a broad spectrum of cancers caused by pathogenic or likely pathogenic (P/LP)  
55 *TP53* germline (or mosaic) variants, 80% of which are missense <sup>1</sup>. Typically, LFS  
56 occurs in three phases, (1) the childhood phase (0-18 years), characterized by a  
57 quartet of early life cancers (adrenocortical carcinoma, ACC; choroid plexus tumor,  
58 CPT; medulloblastoma, MB, and rhabdomyosarcoma, RMS, all of which occur almost  
59 exclusively before age ten years), and a high risk of soft tissue sarcoma (STS),  
60 osteosarcoma (OS), and central nervous system tumors (CNS) in adolescence; (2) the  
61 early adult phase, characterized by premenopausal breast cancer (PBC), multiple STS  
62 and CNS; and (3) the late adult phase, characterized by lung adenocarcinoma (LUAD),  
63 STS, colorectal cancer and prostate cancer <sup>2</sup>. Clinical definitions are traditionally based  
64 on classic LFS criteria <sup>3</sup>, whereas revised Chompret criteria <sup>4</sup> are aimed at identifying  
65 patients for *TP53* mutation testing, covering both childhood and adult common  
66 presentations of LFS. A definition of the phenotypic spectrum of LFS has been  
67 proposed, encompassing (1) phenotypic LFS, defined by the absence of a germline  
68 *TP53* variant in persons/families meeting clinical LFS criteria, i.e., classic LFS or

69 Chompret Category A testing criteria; (2) LFS, defined by the presence of a *TP53*  
70 variant in persons/families meeting LFS testing criteria or with cancer < 18 years; (3)  
71 attenuated LFS (aLFS), defined by the presence of a *TP53* variant in a person/family  
72 with cancer  $\geq$  18 years who does not meet LFS testing criteria; and (4) incidental LFS,  
73 defined by the presence of a *TP53* variant in a person/family without a history of cancer  
74 <sup>5</sup>. This phenotypic definition provides a framework to investigate genotype-phenotype  
75 correlations by classifying *TP53* variants according to their pathogenicity.

76  
77 The p53 protein is a multi-functional transcription factor regulating a complex network  
78 of cellular and systemic anti-proliferative responses <sup>6–8</sup>. Loss of these functions, often  
79 caused by inactivating missense mutations in the *TP53* gene, impairs several  
80 coordinated mechanisms of growth suppression that normally operate to counteract  
81 carcinogenesis <sup>9</sup>. The main functional feature of tumor-associated somatic mutations  
82 is the disruption of DNA binding and transactivation capacity of the p53 tumor  
83 suppressor protein, either by direct mutation and structural alteration of the DNA-  
84 binding domain (DBD), or by destabilization of the oligomerization domain required for  
85 high-affinity DNA-binding (Loss of Function, LOF). Stable mutant proteins can also  
86 exert dominant-negative effects (DNE) over wild-type allele products and have also  
87 been proposed to exert a number of pro-oncogenic gain of function (GOF) effects  
88 documented in experimental cell and animal models <sup>10</sup>, the phenotypic consequences  
89 of which remain unclear in the context of LFS. Systematic large-scale studies have  
90 assessed the impact of thousands of missense variants on biochemical and biological  
91 p53 protein functions in yeast or cell-based experimental assays <sup>11–13</sup>. This wealth of  
92 information, as well as carriers' phenotypic traits, is used by the ClinGen *TP53* expert  
93 panel to inform variant interpretation for clinical purposes  
94 (<https://clinicalgenome.org/affiliation/50013/>) <sup>14</sup>. Of particular interest among functional  
95 datasets is the *TP53* variant transactivation dataset developed over 20 years ago by  
96 C. Ishioka et al. using a yeast-based functional assay <sup>12</sup>. This assay analyzed the  
97 transactivation capacity of a panel of 2,314 variants towards synthetic reporters  
98 controlled by eight different p53 DNA response elements (p53RE). Thus, this dataset  
99 provides the equivalent of eight different “mugshots” for each variant, revealing both  
100 quantitative and qualitative features that capture subtle variations in their capacity to  
101 bind and transactivate different sequences matching the p53 DNA-binding consensus.  
102

103 In this study, we described and tested a new classification of *TP53* missense variants  
104 based on a revisited analysis of Kato's yeast-based transactivation (YTA) data (**Figure**  
105 **1, graphical abstract**). We have applied an iterative clustering approach to separate  
106 *TP53* missense variants into four classes (A, B, C, D) as compared to  
107 nonsense/frameshift variants (class 0) that are considered as completely inactivating  
108 the p53 protein. Mapping these classes on phenotypic LFS data from the public  
109 repository of germline *TP53* variants curated at NCI (<https://tp53.isb-cgc.org/>) revealed  
110 that each class is associated with defined phenotypic traits within the LFS spectrum.  
111 Our results provide a refined resolution of genotype-phenotype correlations in LFS as  
112 well as insights on structural/functional features that specify variant pathogenicity.

113

## 114 **RESULTS & DISCUSSION**

115

### 116 ***TP53* variant clustering**

117

118 An iterative hierarchical Ward's clustering method was used to interrogate the  
119 missense variant dataset developed by Ishioka and collaborators in yeast based  
120 functional assays <sup>12</sup>. We identified 16 iterative clusters of various sizes based on  
121 variant similarities in their capacity to differentially activate eight promoters containing  
122 different versions of p53 DNA consensus elements (from 613 variants in Cluster 2\_2\_1  
123 to 5 variants in Cluster 3) (**Figure S1 and Figure S2A**). Each cluster differed by the  
124 quantitative and qualitative features of their transcriptional activity, ranging from  
125 complete loss of activity towards all promoters (cluster 1\_1\_1, "triple\_1") to enhanced  
126 transcriptional activity (compared to wild-type p53) towards at least some promoters  
127 (cluster 3, "supertrans"), with a broad diversity of clusters with intermediate qualitative  
128 and quantitative features.

129

130 To map these clusters onto the LFS tumor spectrum, we grouped them into four  
131 classes (A to D), broadly reflecting a gradient of activity with A having the lowest overall  
132 transcriptional activity and D the highest, and B and C displaying intermediate and  
133 heterogeneous activities towards different reporters (**Figure S2**). The list of the 2,314  
134 *TP53* missense variants and the corresponding clusters and classes is presented in  
135 **Table S1**. Classes showed clear differences in variant distribution within the p53  
136 protein structure (**Figure 2A and S3**) and in their predicted structural/functional effects

137 **(Figure S4)**. When compared with biophysical prediction scores (SIFT, AGVGD)<sup>15,16</sup>  
138 and integrative structural and functional scores<sup>17</sup>, classes highlighted a gradient from  
139 A to D, with A and B being enriched in deleterious and non-functional features while C  
140 and D were enriched in non-deleterious and functional features. Class A included all  
141 common *TP53* cancer mutation hotspots and was enriched in variants at residues  
142 located within the surface of the p53 protein in direct contact with DNA, in structural  
143 elements supporting the DNA binding surface, or in structural motifs required for the  
144 cohesion of the p53 tetramerization domain. Class B included variants mapping to the  
145 DBD of p53, albeit at different residues than class A, mostly located within defined  
146 sections of the beta-sheets that constitute the scaffold of the DBD as well as in loops  
147 exposed at the surface of the protein but not within its DNA-binding surface. Class C  
148 and D were enriched in variants that mapped to the N-terminus or to the extreme C-  
149 terminus of p53. Class C, in particular, was enriched in variants at residues of the C-  
150 terminal regulatory domain with multiple post-translational regulatory sites poorly  
151 represented in other classes.

152  
153 We next mapped the distribution of classes A-D in three *TP53* variant datasets: cancer-  
154 related germline variants (NCI; <https://tp53.isb-cgc.org/>), cancer related somatic  
155 variants (COSMIC; <https://cancer.sanger.ac.uk/cosmic>) and non-cancer related  
156 germline variants (gnomAD; <https://gnomad.broadinstitute.org/>) **(Figure 2B)**. Class A  
157 variants were enriched by factors of 4.5 and 3.3 fold in the COSMIC and NCI datasets,  
158 respectively but were counter-selected (0.2 fold) in the gnomAD dataset. Likewise,  
159 albeit to a lesser extent, class B variants showed positive selection in COSMIC (1.1)  
160 and NCI (1.3) datasets, but not in gnomAD (0.2). In contrast, class D variants were  
161 enriched in gnomAD (1.8) and counter-selected in COSMIC (0.1) and NCI (0.2),  
162 whereas class C was not enriched in any of the datasets. These results are compatible  
163 with the notion that classes A to D correspond to a gradient of cancer-related p53  
164 dysfunction.

165  
166 **Variant classes are associated with distinct phenotypic patterns within the LF**  
167 **spectrum**

168  
169 To determine whether variant classes could predict tumor phenotypes within the broad  
170 LF spectrum, we analyzed lifetime cancer accrual and tumor patterns using data

171 compiled in the NCI germline *TP53* mutation database (<https://tp53.isb-cgc.org/>)<sup>18</sup>.  
172 This database assembles information retrieved from the literature on 3,446 individuals  
173 (1,522 families) with germline *TP53* variants (4,031 cancer diagnoses). As a basis for  
174 comparison, we added a class “zero” (0) that included variants considered as “null” for  
175 p53, i.e., non-missense variants (nonsense, frameshift,) that disrupt the production of  
176 a functional p53 protein (**Figure S5**). Class 0 thus includes variants considered to have  
177 completely lost wild-type p53 function. **Figure 3A** shows that class A variants were  
178 found in 1426 (53%) patients, followed by class 0 (552, 21%), B (290, 11%), C (242,  
179 9%), and D (171, 6%). Gender distribution differed among classes, with a lower  
180 proportion of males in classes B, C and D (31.4%, 26.7%, and 32%, respectively) than  
181 in classes 0 and A (40.9% and 40.6%, respectively) (**Figure 3B**). With respect to  
182 lifetime cancer accrual, classes 0 and A were associated with the most severe profiles  
183 (median age at first diagnosis = 28 years) (**Figure 3C-E**). Classes C and D were  
184 associated with attenuated accrual profiles (median age = 41 years), whereas class B  
185 showed an intermediate and distinct profile (median age = 33 years), characterized by  
186 rapid accrual during childhood (similar to classes A and 0) and slower accrual during  
187 adolescence and adulthood. This gradient of pathogenicity was reflected in the  
188 proportion of carriers with multiple cancers as well as cancer free (**Figure 3F-G**) and  
189 was consistent with current definitions of clinical phenotypes (**Figure I-J**). Of note,  
190 Variants in established cancer predisposition genes other than *TP53* were more  
191 frequently found in carriers of class D variants than in carriers of any other variant class  
192 (**Figure 3H**).

193  
194 Comparison across classes revealed statistically significant differences in tumor  
195 patterns (**Figure 4, Table S2, Figures S6 and S7**). Classes 0 and A shared topological  
196 and morphological tumor patterns that recapitulated the broad phenotype of the LF  
197 spectrum. This included all LFS “signature” cancers such as childhood ACC, CPT,  
198 RMS, and MB, teenage OS, and early adulthood breast phyllodes cancers. There  
199 were, however, small but statistically significant differences between 0 and A, the latter  
200 presenting with a higher proportion of brain cancers (BR) (RR = 1.53, 95% CI [1.16-  
201 2.05]), including in particular CPT (**Figure 4B-C, Table S2 and Figure S6**) compared  
202 to class 0. This observation suggests that, whereas in most tissues class A variants do  
203 not convey a stronger predisposition than class 0 (LOF), they could exert limited  
204 dominant GOF effects by accelerating tumor onset in specific tissues (e.g. CPT)

205 without changing the overall phenotypical pattern of LFS. Importantly, we could not  
206 identify a subset of variants within class A that would be responsible for these effects  
207 (e.g. class A variants overrepresented in CPT compared to other cancers). Overall,  
208 these observations suggest that such GOF effects in LFS depend upon cell and tissue  
209 context rather than upon specific variant structural and functional properties.

210  
211 Compared to 0 and A, class B presented with a slightly smaller proportion of many of  
212 the cancers that define the LF spectrum (**Figure 4B-C and Figure S6**), with the notable  
213 exception of ACC (RR B vs A = 2.74 (95% CI [1.78;4.143.90]; RR B vs 0 = 3.12 (95%  
214 CI [1.84-5.34]) (**Table S2**). In class B, ACC was by far the most common cancer form  
215 in children (up to the age of 10), accounting for the fact that cancer accrual in early life  
216 was as rapid in that class than in classes 0 or A (**Figure 3C**), despite the relative rarity  
217 of some of the other childhood “signature” LFS cancers in class B carriers (i.e., RMS,  
218 MB) (**Figure S6**). Compared to A, class B also showed a higher proportion of carriers  
219 who were cancer-free (**Figure 3G**) as well as differences in the predominant  
220 morphologies of CNS (glioblastomas) (**Figure 4B, Figure S6**). As a result, carriers of  
221 class B variants showed a slightly delayed median age of tumor onset as compared to  
222 classes 0 and A, but a similar pattern of cancer accrual during childhood. Thus, class  
223 B identified variants with a slightly distinct risk profile within the LF spectrum. These  
224 variants were mostly distributed within structural motifs of the DBD that are not in  
225 contact with DNA and showed less severe structural and functional features than class  
226 A. Compared to other classes, class B variants also showed a remarkable  
227 heterogeneity in their capacity to transactivate different YTA promoters. Overall, these  
228 observations suggest that the more distinct effects of class B variants are due to the  
229 retention of partial and selective p53 transcriptional activity. On the other hand, the  
230 high prevalence of ACC in carriers of class B variants suggests that perinatal adrenal  
231 cortical cells are exquisitely sensitive to wild-type p53 dosage and that variants  
232 mediating only partial loss of wild-type p53 activity may suffice to enhance the risk of  
233 early ACC.

234  
235 Class C contains less penetrant variants, which nevertheless predispose to cancers  
236 typical of the LF spectrum, in particular ACC (**Figure 4B-C and Figure S6**). Compared  
237 to 0, A and B, class C presented with an attenuated risk of all cancers characterizing  
238 the LF spectrum, except ACC (RR C vs A = 2.05 (95%CI [1.20-3.34]) and breast

239 cancers (BC) (RR C vs A = 1.75 (95% CI [1.32-2.31]) (**Figure 4B-C, Figure S6, Table**  
240 **S2**). In particular, class C carriers rarely presented with OS compared to class A or 0  
241 carriers (**Figure S6**). Likewise, CPC and RMS were vastly underrepresented, and MB  
242 were absent (**Figure S6**). Class C also presented with a higher proportion of cancer-  
243 free carriers than any other class (**Figure 3G**). Thus, class C appears to be associated  
244 with a cancer risk that only partially recapitulates the LF spectrum. Interestingly, this  
245 class included two founder variants qualified as “hypomorphs”, R337H (Brazilian-  
246 centric)<sup>19</sup> and Y107H (African-centric)<sup>20</sup>, which retain partial wild-type p53 activities  
247 when tested in standard conditions *in vitro* but nevertheless specify a significant risk  
248 for diverse cancers of the LF spectrum in both children and adults. It has been  
249 suggested that these variants may require synergistic alterations in other pathways to  
250 express their full pathogenic potential. This hypothesis is supported by the discovery  
251 that, in R337H carriers, an inactivating variant of the putative tumor  
252 suppressor *XAF1* (E134\*/Glu134Ter/ rs146752602) enhances the risk of developing  
253 sarcomas<sup>21</sup>. Thus, class C may be enriched in incompletely inactivating variants that  
254 require genetic, epigenetic, or metabolic/biochemical complementation to express their  
255 full pathogenic potential.

256  
257 Class D presented with the most attenuated pattern within the LF spectrum.  
258 “Signature” LF cancers such as early ACC, CPT, MB, OS, and phyllodes tumors of the  
259 breast were, if not completely absent, significantly less represented than in A, B or C  
260 (**Figure 4B-C, Figure S6**). In contrast, the most represented cancer types in D were  
261 malignancies involving the hematopoietic system, the most common form of sporadic  
262 neoplasia in children, independent of germline status. Class D variants retained quasi-  
263 wild-type p53 transcriptional properties for at least half of the YTA promoters tested,  
264 consistent with their ClinVar annotation as benign or likely benign (B/LB). In line with  
265 these data, class D carriers also more frequently harbored pathogenic variants in other  
266 established cancer predisposition genes than carriers of any other class (**Figure 3H**).  
267 These observations suggest that carrying a class D variant may not in itself predispose  
268 to LFS. However, it cannot be excluded in specific contexts (e.g. inheritance of other  
269 cancer predisposing variants or genetic modifiers), some class D variants may  
270 contribute to enhance the risk of LF spectrum cancers. Thus, great care should be  
271 exercised when considering such variants in genetic counselling.

272



273 The overall cancer phenotypes of each variant class are summarized in a heatmap  
274 (**Figure 4C**), highlighting an LF tumor-specific phenotypic gradient from classes 0 and  
275 A to class C. Classes A and 0 were associated with the most severe forms of LFS,  
276 class B identified a distinct, slightly less penetrant form, with ACC as the most frequent  
277 early life cancer, class C was correlated to an attenuated form nevertheless  
278 predisposing to cancers typical of the LF spectrum (ACC, BC), whereas class D did  
279 not appear to confer a risk for LFS cancers.

280

### 281 **Dissecting variant classes using cell-based functional scores**

282

283 Despite their high sensitivity and selectivity for distinct p53RE, YTA screens may lack  
284 the specificity of phenotypic screens in human cells addressing physiologically  
285 meaningful p53 functionalities. We thus sought to determine whether the functional  
286 scores obtained in systematic human cell-based assays were consistent with our YTA  
287 classes and could identify additional groups of variants associated with distinct LF  
288 phenotypes. First, the stability and coherence of YTA classes was challenged with the  
289 functional scores developed by Giacomelli et al.<sup>11</sup> (phenotypic selection model) and  
290 Kotler et al.<sup>13</sup> (relative fitness score). **Figure 5** shows that these functional scores were  
291 broadly consistent with YTA classes, with A having the highest and D the lowest  
292 median scores. However, individual variant scores were widely distributed within each  
293 class, suggesting that YTA classes may contain variants that differ by their functional  
294 properties when overexpressed in human cells. To further assess this heterogeneity,  
295 we separated variants in each class into groups according to the quartiles of their  
296 human cell-based functional scores (**Figures S8, S9**). Results show that cancer  
297 accrual in class A carriers was similar across all quartiles and thus independent of  
298 human cell-based scores. Whereas heterogeneity was found for classes B, C and D,  
299 it reached statistical significance only for class C ( $p < 0.0001$ , Giacomelli's phenotypic  
300 selection model;  $p = 0.0073$ , Kotler's relative fitness score), highlighting that this class  
301 contains variants that are more functionally heterogeneous than variants in other  
302 classes. Similarly, stability analyses using TP53\_PROF, an integrative computational  
303 score<sup>17</sup>, did not show any additional benefit of using this score for stratifying variants  
304 according to their pathogenicity within each of the YTA classes (**Figure S10**). Overall,  
305 these results show that YTA classes were remarkably robust and sensitive in predicting  
306 cancer accrual and cancer phenotypes in germline *TP53* variant carriers.

307

## 308 **Clinical significance of YTA classes**

309

310 ClinVar expert panel annotations (<https://clinicalgenome.org/affiliation/50013/>) are  
311 based on expert consensus review of genotype/phenotype correlations and are the  
312 current standard for interpreting *TP53* germline variants for clinical purposes <sup>14</sup>.  
313 However, these annotations cover only a proportion of all missense variants in the NCI  
314 germline dataset. We thus assessed the concordance between YTA classes and  
315 ClinVar expert panel as a first step to determine whether YTA classes could assist in  
316 the clinical evaluation of variants that have not yet been annotated to date. **Figure 6A**  
317 shows that YTA classes were broadly concordant with expert panel annotations, with  
318 A and B classes mostly represented among P/PL variants and C and D classes mostly  
319 represented among B/LB variants. The only exception was D49H, a class A variant  
320 which was annotated as LB by ClinVar. Of note, there is only a single family (2 patients)  
321 with this variant documented in the NCI germline dataset. This family matched  
322 phenotypic criteria for TP53 mutation testing (Chompret's criteria; embryonal RMS of  
323 the cervix at 2 years and Hodgkin's lymphoma at 15 years) <sup>22</sup>. D49H has also been  
324 reported in 6 Japanese patients with family history of cancer, one of whom matched  
325 Chompret's criteria <sup>23</sup>. This patient carried another germline class A TP53 variant,  
326 A159D. Overall, these observations suggest that D49H should be considered with  
327 caution as a rare, potentially pathogenic variant.

328 Interestingly, variants annotated as "Uncertain Significance" (VUS) were  
329 predominantly class C variants, followed by class B and D variants, suggesting that  
330 YTA classes may help in resolving ambiguities in variant annotations. Furthermore,  
331 variants annotated by the expert panel could be perfectly separated on the basis of  
332 cancer accrual according to YTA classes ( $p < 0.0001$ ), recapitulating the distinct  
333 accrual pattern of each class (e.g the difference in cancer accrual between class A and  
334 class B variant carriers). (**Figure 6B and 3C**). These results suggest that YTA classes  
335 are remarkably consistent with expert panel annotations.

336

337 Next, we evaluated to which extent YTA classes could predict cancer accrual in  
338 subjects carrying variants not annotated by the expert panel. Within classes A, B and  
339 C, cancer accrual in carriers of non-expert panel variants was almost perfectly aligned  
340 with the one of expert panel curated variants (**Figure 6C**).

341

342 To further assess the usefulness of YTA classes in a clinical context, we examined  
343 cancer accrual and tumor patterns according to classes in three cohorts of carriers  
344 recruited in different high risk cancer predisposition clinics in Germany (n = 146, LFS  
345 Registry in Hannover), France (n = 578, French LFS Cohort) and Canada (n = 97,  
346 Toronto LFS Cohort). These cohorts are maintained and annotated mainly  
347 independently of the NCI germline dataset. **Figure 7** shows that, in each of the cohorts,  
348 YTA classes correctly predicted cancer accrual and distinguished among carriers with  
349 quantitative and qualitative differences in LF spectrum. In all three cohorts, class A  
350 carriers presented the most severe phenotype (similar to class 0 in the German and  
351 Canadian cohort). Compared to A, class B carriers had a distinct and less penetrant  
352 phenotype, characterized by high risk of early life ACC and slightly delayed overall  
353 cancer accrual. Class C carriers often had attenuated phenotypes, nevertheless  
354 including cancers typical of the LF spectrum (i.e., ACC and PBC) but excluding most  
355 other typical LF childhood cancers, whereas in class D tumor patterns tended to be  
356 more heterogeneous, with the majority of carriers not matching LF spectrum definitions  
357 (**Figure S11**). Overall, these observations support that YTA classes can help to predict  
358 specific patterns of risk in germline carriers and could be particularly helpful for  
359 assessing the risk of novel variants as well as variants not yet annotated by expert  
360 panels or ClinVar.

361

## 362 **CONCLUSIONS**

363

364 This new classification of *TP53* missense variants into 4 classes supports a robust  
365 interpolation between genotypes (variant characteristics) and phenotypes (cancer risk  
366 and spectrum). The classification is based on quantitative and qualitative similarities  
367 between variants in a yeast-based transcriptional assay. Whereas the yeast readout  
368 is based on variants' interaction with synthetic p53RE (DNA binding capacity), YTA  
369 classes correctly separate severe from mild or benign variants in all structural domains  
370 of the p53 protein, including transactivation domain, DBD and tetramerization domain.  
371 The coherence and robustness of YTA classes is demonstrated by the fact that  
372 implementing human cell-based functional scores within YTA classes did not break  
373 them into further subgroups, suggesting that yeast-based readouts are precise and  
374 sensitive enough by themselves to allocate variants to clinically meaningful groups.

375 Overall, these observations imply that, collectively, the 8 yeast-based readouts  
376 available for each variant can be used as sensitive “mugshots” for variant risk  
377 assessment.

378 This classification provides new insights into the concept of attenuation within the LF  
379 spectrum <sup>5</sup>. The term aLFS has been coined to identify an LF phenotype defined by  
380 the presence of a germline P/LP *TP53* variant in a person with any cancer who does  
381 not meet LFS genetic testing criteria and has no cancer diagnosed before age 18  
382 years. Our analysis did not identify a specific YTA class matching this phenotypic  
383 definition. Rather, we observed a gradient in the proportion of individuals with aLFS  
384 phenotype from class 0 or A (< 17-21%) to class C or D (> 50-61%) (**Figure 3J**).  
385 Remarkably, even among carriers who met LFS genetic testing criteria, YTA classes  
386 underscored a gradient of phenotypic attenuation, with carriers of B or C variants  
387 presenting, on average, with a less severe phenotype than carriers of A or 0 variants.  
388 Another key message is that risk attenuation in relation to YTA classes does not obey  
389 to a unique, linear rule for all cancers that characterize the LF spectrum. In particular,  
390 carriers of B or C variants retain a risk for early ACC at least equal to classes 0 and A,  
391 supporting that predisposition to this cancer can be high even with relatively mild *TP53*  
392 variants. In contrast, other “signature” LF cancers such as OS, CPT, MB or RMS, were  
393 remarkably more prevalent in carriers of 0 or A than in carriers of B, C or D variant  
394 classes. A limitation of this study is that it does not take into account the fact that at  
395 least some mutations causing missense variants may also cause aberrant mRNA  
396 splicing patterns, resulting in loss of p53 protein expression. Such effects may confer  
397 greater severity to variants currently solely interpreted as missense. So far, these  
398 effects on splicing have not been evaluated in systematic functional assays. Overall,  
399 our integrative genotypic/phenotypic analysis provides a new angle to predict individual  
400 and familial risk in germline variant carriers, as well as a basis to identify hypomorphic  
401 variants that require genetic or epigenetic modification to express their full pathogenic  
402 potential.

## 403 MATERIAL AND METHODS

404  
405 **Iterative clustering on transactivation data.** We retrieved transactivation scores  
406 from 2,314 *TP53* variants <sup>12</sup> on eight *TP53* promoters (WAF1nWT, MDM2nWT,  
407 BAXnWT, h1433snWT, AIP1nWT, GADD45nWT, NOXAnWT, P53R2nWT). We

408 performed hierarchical Ward clustering in R v3.6.1 with Euclidean distance, and  
409 arbitrarily chose three clusters. We performed a second iteration of clustering in the  
410 sub-clusters including more than 50 mutations. Up to three layers of clustering  
411 iterations were processed. A total of 16 distinct clusters were thus defined.  
412 Dendrograms were retrieved with *dendextend* package, and heatmaps were built using  
413 *pheatmap* package.

414  
415 **YTA classes consolidation.** Final groups of clusters (YTA classes) were defined via  
416 the following approach: the most disrupted variants (cluster 1\_1\_1) were assigned to  
417 class A; variants of the upper layer (layer 1\_1 except cluster 1\_1\_1) were defined as  
418 class B; variants of the next upper layer (layer 1 except the layer 1\_1) were defined as  
419 class C; finally, the less disrupted variants (all variants except layer 1) were defined as  
420 class D.

421  
422 **Confrontation of YTA classes with existing scores for TP53.** We confronted our  
423 classes to various scores attributed to TP53: the transactivation classes as previously  
424 defined by the analysis of transactivation in yeast assays <sup>12</sup>, the Sorting Intolerant from  
425 Tolerant (SIFT) database (<https://sift.bii.a-star.edu.sg>) <sup>16</sup>, the Align Grantham Variation  
426 Grantham Deviation (AGVGD) database (<http://agvgd.hci.utah.edu>) <sup>15</sup>, the TP53  
427 prediction of functionality (TP53\_PROF) <sup>17</sup>, the TP53 functionality scores obtained in  
428 human cell lines <sup>11,13</sup> and the ClinVar database which aggregates information about  
429 genomic variation and its relationship to human health  
430 (<https://www.ncbi.nlm.nih.gov/clinvar>) <sup>24</sup>. The confrontation of the classes with the  
431 various TP53 scores was performed using Pareto Plot or Pie Chart representations for  
432 categorical values and Scattered Plots and Violin Plots for numerical values (R, *ggplot2*  
433 package).

434  
435 **Structural mapping of YTA classes.** The distribution of TP53 mutated residues along  
436 the TP53 sequence and domains was analyzed for each YTA class. Heatmaps were  
437 used to highlight the pattern of distribution of variants along TP53 sequence in the  
438 different YTA classes (R, package *pheatmap*). The proportion of variants within each  
439 TP53 domain is depicted using cumulative histograms (R, package *ggplot2*). The  
440 localization of mutations in the p53 protein structure was assessed using the software  
441 ChimeraX <sup>25</sup> (<https://www.cgl.ucsf.edu/chimerax>) together with PDB files of the TP53

442 binding domain 3KMD<sup>26</sup> and the *TP53* tetramerization domain 1C26<sup>27</sup>, as well as the  
443 alpha-fold modeled structure<sup>28</sup>.

444  
445 **YTA classes distribution in datasets.** The occurrence of *TP53* variants assigned to  
446 YTA classes was assessed in different databases: tumor-based variants in the Cosmic  
447 database v97 (<https://cancer.sanger.ac.uk/cosmic>)<sup>29</sup>, normal sample-based variants  
448 in the gnomAD database v3.1.2 (<https://gnomad.broadinstitute.org>)<sup>30</sup>, and *TP53*  
449 germline variants database R20 released in July 2019 and hosted at the NCI  
450 (<https://tp53.isb-cgc.org>)<sup>18</sup>. We used the protein mutation information in the databases  
451 to analyze the distribution of variants into YTA classes. Pie charts are used to show  
452 distribution of variant classes in the different databases, and numerical counts are  
453 indicated (R, *ggplot2* package).

454  
455 **Selection of individuals from the LF spectrum database.** We analyzed the YTA  
456 classes on clinical data from the LF spectrum database R20 (germline *TP53* variants),  
457 released in July 2019 and hosted at the NCI (<https://tp53.isb-cgc.org>)<sup>18</sup>. This database  
458 recapitulates clinical data of patients carrying *TP53* germline variants. The database  
459 contains data from 3,446 individuals (from 1,522 families) reported in the scientific  
460 literature since 1990. Individuals carrying several *TP53* variants were excluded from  
461 our analysis because of complexity to determine the contribution of individual variants  
462 in these patients. Also, individuals carrying the *TP53* p.R337H Brazilian variant who  
463 were not recruited through familial history of cancer were removed, because of bias of  
464 analysis (in column Ref\_ID: 138, 196, 259, 323 and 400 were selected in the LF  
465 spectrum database). Individuals carrying *TP53* missense variants were dispatched in  
466 groups corresponding to the YTA classes (A, B, C, D). The remaining individuals,  
467 carrying non-missense variants were selected based on the type of effect of the variant  
468 in order to build a class of reference containing non-functional (LOF) variants. We only  
469 kept nonsense and frameshift (ft) variants (from column "Effect") to consolidate a null  
470 class (named class 0) corresponding to disruption of the full-length protein.

471  
472 **Genotype-Phenotype correlations of YTA classes within the LF spectrum**  
473 **database.** Lifetime cancer accrual for the YTA classes was assessed using the age of  
474 first cancer onset or the cancer-free age of an individual. Patients without age  
475 indication were not considered for this analysis. The age of median cancer accrual

476 (and confidence intervals at 95%) was extracted and a Log-Rank Mantel-Cox test was  
477 run to assess the significance of differences between groups. These analyses were  
478 performed using R and the *survival* and *survminer* packages. Information about  
479 individuals' sex was retrieved in the corresponding column (Sex). The proportion of  
480 individuals with multiple cancers versus individuals with one cancer was assessed for  
481 each YTA class. The proportion of cancer-free individuals compared to individuals with  
482 cancer was assessed for each class. Tumor distribution was determined in the YTA  
483 classes by analyzing all tumors described in the dataset (primary and secondary  
484 malignancies). We used the topology (organs) and the morphology (subtypes)  
485 information available in the LF spectrum database, and we consolidated groups based  
486 on organs of interest for the study of LFS (adrenal gland, brain, bone, soft tissue,  
487 breast, hematopoietic system, and the mix of all other organs) as well as specific  
488 cancer types (ACC, OS, CPT, MB, glioblastoma, phyllodes tumors, and RMS).  
489 Graphical representation of proportions of tumor types was performed using R  
490 (package *ggplot2*). Distribution of tumor topology was compared between YTA classes  
491 by performing a Khi2 test (multiple pairwise comparison) to obtain a risk ratio,  
492 confidence intervals at 95% and an associated adjusted p-value, using R software.  
493 Mapping of age-specific tumor distribution within YTA classes was assessed by  
494 generating rain-cloud plots (R, package *ggplot2*). Finally, the relationship between YTA  
495 classes and the clinical definitions of LFS was evaluated using the LFS spectrum  
496 classification<sup>5</sup> and the column "Class" from the IARC/NCI database, to build bar-plots  
497 of proportions of individuals within each clinical class.

498  
499 **Challenging YTA classes with other functional scores.** YTA classes were  
500 separated based on the *TP53* functionality scores obtained in human cell lines<sup>11,13</sup>.  
501 For each YTA class, *TP53* variants were separated into four groups by quartile values.  
502 The 1<sup>st</sup> quartile corresponds to lower scores and the 4<sup>th</sup> quartile corresponds to higher  
503 scores (most disrupted functionality of p53). YTA classes were also separated based  
504 on the *TP53* prediction of functionality (TP53\_PROF, Deleterious and Non-  
505 Deleterious)<sup>17</sup> and the ClinVar database annotation  
506 (<https://www.ncbi.nlm.nih.gov/clinvar>)<sup>24</sup>. Cancer accrual of the subgroups of each YTA  
507 class was analyzed and the median age and statistical differences were extracted  
508 similar to YTA class comparison.

509

510 **Validation cohorts.** Three validation cohorts originating from three different clinics  
511 were used to verify the consistency of our observations for the YTA classes.

- 512 - The “LFS Registry in Hannover”, Germany, recruits patients with a previously  
513 established diagnosis of LFS. Only patients carrying pathogenic or likely  
514 pathogenic variants (according to Fortuno criteria) are included.
- 515 - The “French LFS Cohort” has included germline missense TP53 variants from  
516 the French registry (Rouen, France) identified in cancer patients who benefited  
517 from TP53 analysis.
- 518 - The “Toronto LFS Cohort”, Canada, is a multi-institutional collection of data from  
519 patients and families carrying germline pathogenic variants that were referred  
520 to The Hospital for Sick Children.

521

522

## 523 **AUTHOR CONTRIBUTIONS**

524 EM, NL and PH conceived and designed the study. PH supervised research. NL  
525 performed hierarchical clustering. EM performed bioinformatic analysis and graphical  
526 representations with the help of SB. EM analyzed genotype-phenotype correlations  
527 with the help of CF. JP, CK, GB, NF and DM provided clinical data. AA and FC assisted  
528 EM with statistical analyses. JP, CK, GB, NF, DM, MIA, AL and CG contributed to the  
529 discussion and interpretation of variant classes. EM and PH wrote the manuscript. All  
530 authors critically revised the manuscript for important intellectual content and approved  
531 the version for publication.

532

## 533 **ACKNOWLEDGMENTS**

534 EM was a recipient of a European MSCA individual fellowship (846806) and a  
535 Foundation ARC (France) postdoctoral fellowship. This work is supported by the IDEX  
536 of University Grenoble Alpes (LIFE project) and by the ERiCAN program of Foundation  
537 MSDAvenir (France). CPK is supported by the BMBF ADDRess (01GM2205A) and by  
538 the Deutsche Kinderkrebsstiftung (DKS2021.25).

539

## 540 **ABBREVIATIONS**

541 ACC: Adrenal Cortical Carcinoma

542 AGVGD: Align Grantham Variation and Grantham Deviation

543 aLFS: attenuated LFS



544 BC: Breast Cancer  
545 BR: Brain Cancer  
546 B/LB: Benign or Likely Benign  
547 CNS: Central Nervous System Tumors  
548 CRC: Colorectal Cancer  
549 COSMIC: Catalogue of Somatic Mutations in Cancer  
550 CPT: Choroid Plexus Tumors  
551 DBD: DNA Binding Domain  
552 DNE: dominant-negative effect  
553 GOF: Gain of Function  
554 gnomAD: Genome Aggregation Database  
555 LF: Li-Fraumeni  
556 LFS: Li-Fraumeni Syndrome  
557 LOF: loss of function  
558 LUAD: lung adenocarcinomas  
559 MB: Medulloblastoma  
560 OS: Osteosarcoma  
561 PBC: Premenopausal Breast Cancer  
562 P/LP: Pathogenic or Likely Pathogenic  
563 P53RE: p53 Response Elements  
564 RMS: Rhabdomyosarcoma  
565 SIFT: Sorting Intolerant From Tolerant  
566 STS: Soft Tissue Sarcoma  
567 VUS: Variants of Unknown Significance  
568 YTA: Yeast Transactivation Assay

## 569 REFERENCES

- 570 1. Bougeard, G. *et al.* Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. *J*  
571 *Clin Oncol* **33**, 2345–2352 (2015).
- 572 2. Amadou, A., Achatz, M. I. W. & Hainaut, P. Revisiting tumor patterns and penetrance  
573 in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. *Curr*  
574 *Opin Oncol* **30**, 23–29 (2018).

- 575 3. Li, F. P. *et al.* A cancer family syndrome in twenty-four kindreds. *Cancer Res* **48**,  
576 5358–5362 (1988).
- 577 4. Frebourg, T. *et al.* Guidelines for the Li-Fraumeni and heritable TP53-related cancer  
578 syndromes. *Eur J Hum Genet* **28**, 1379–1386 (2020).
- 579 5. Kratz, C. P. *et al.* Analysis of the Li-Fraumeni Spectrum Based on an International  
580 Germline TP53 Variant Data Set: An International Agency for Research on Cancer  
581 TP53 Database Analysis. *JAMA Oncology* **7**, 1800–1805 (2021).
- 582 6. Kasthuber, E. R. & Lowe, S. W. Putting p53 in Context. *Cell* **170**, 1062–1078  
583 (2017).
- 584 7. Kruiswijk, F., Labuschagne, C. F. & Vousden, K. H. p53 in survival, death and  
585 metabolic health: a lifeguard with a licence to kill. *Nat Rev Mol Cell Biol* **16**, 393–405  
586 (2015).
- 587 8. Levine, A. J. p53: 800 million years of evolution and 40 years of discovery. *Nat Rev*  
588 *Cancer* **20**, 471–480 (2020).
- 589 9. Hainaut, P. & Pfeifer, G. P. Somatic TP53 Mutations in the Era of Genome Sequencing.  
590 *Cold Spring Harb Perspect Med* **6**, a026179 (2016).
- 591 10. Stein, Y., Aloni-Grinstein, R. & Rotter, V. Mutant p53 oncogenicity: dominant-negative  
592 or gain-of-function? *Carcinogenesis* **41**, 1635–1647 (2020).
- 593 11. Giacomelli, A. O. *et al.* Mutational processes shape the landscape of TP53 mutations  
594 in human cancer. *Nat Genet* **50**, 1381–1387 (2018).
- 595 12. Kato, S. *et al.* Understanding the function-structure and function-mutation  
596 relationships of p53 tumor suppressor protein by high-resolution missense  
597 mutation analysis. *Proc Natl Acad Sci U S A* **100**, 8424–8429 (2003).

- 598 13. Kotler, E. *et al.* A Systematic p53 Mutation Library Links Differential Functional  
599 Impact to Cancer Mutation Pattern and Evolutionary Conservation. *Mol Cell* **71**, 178-  
600 190.e8 (2018).
- 601 14. Fortunato, C. *et al.* Specifications of the ACMG/AMP variant interpretation guidelines  
602 for germline TP53 variants. *Hum Mutat* **42**, 223–236 (2021).
- 603 15. Mathe, E. *et al.* Computational approaches for predicting the biological effect of p53  
604 missense mutations: a comparison of three sequence analysis based methods.  
605 *Nucleic Acids Res* **34**, 1317–1325 (2006).
- 606 16. Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. *Genome Res*  
607 **11**, 863–874 (2001).
- 608 17. Ben-Cohen, G. *et al.* TP53\_PROF: a machine learning model to predict impact of  
609 missense mutations in TP53. *Brief Bioinform* **23**, bbab524 (2022).
- 610 18. de Andrade, K. C. *et al.* The TP53 Database: transition from the International Agency  
611 for Research on Cancer to the US National Cancer Institute. *Cell Death Differ* **1–3**  
612 (2022) doi:10.1038/s41418-022-00976-3.
- 613 19. Achatz, M. I. W. *et al.* The TP53 mutation, R337H, is associated with Li-Fraumeni and  
614 Li-Fraumeni-like syndromes in Brazilian families. *Cancer Lett* **245**, 96–102 (2007).
- 615 20. Indeglia, A. *et al.* An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of  
616 p53-Mediated Tumor Suppression. *Cancer Discov* **13**, 1696–1719 (2023).
- 617 21. Pinto, E. M. *et al.* XAF1 as a modifier of p53 function and cancer susceptibility. *Sci Adv*  
618 **6**, eaba3231 (2020).
- 619 22. Yamazaki, F. *et al.* Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-  
620 Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation. *J*  
621 *Pediatr Hematol Oncol* **40**, e195–e197 (2018).

- 622 23. Yamaguchi, K. *et al.* Prevalence of low-penetrant germline TP53 D49H mutation in  
623 Japanese cancer patients. *Biomed Res* **37**, 259–264 (2016).
- 624 24. Landrum, M. J. *et al.* ClinVar: public archive of interpretations of clinically relevant  
625 variants. *Nucleic Acids Res* **44**, D862–868 (2016).
- 626 25. Pettersen, E. F. *et al.* UCSF ChimeraX: Structure visualization for researchers,  
627 educators, and developers. *Protein Sci* **30**, 70–82 (2021).
- 628 26. Chen, Y., Dey, R. & Chen, L. Crystal Structure of the p53 Core Domain Bound to a Full  
629 Consensus Site as a Self-Assembled Tetramer. *Structure* **18**, 246–256 (2010).
- 630 27. Jeffrey, P. D., Gorina, S. & Pavletich, N. P. Crystal structure of the tetramerization  
631 domain of the p53 tumor suppressor at 1.7 angstroms. *Science* **267**, 1498–1502  
632 (1995).
- 633 28. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature*  
634 **596**, 583–589 (2021).
- 635 29. Tate, J. G. *et al.* COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids*  
636 *Research* **47**, D941–D947 (2019).
- 637 30. Gudmundsson, S. *et al.* Variant interpretation using population databases: Lessons  
638 from gnomAD. *Human Mutation* **n/a**,

639

## 640 **FIGURE LEGENDS**

641

642 **Figure 1: Summary / Graphical Abstract.**

643

644 **Figure 2: Distribution of TP53 variants from YTA classes across TP53 structure**  
645 **and datasets. A.** Localization of TP53 missense variants along the TP53 sequence  
646 (left panel). Heatmap showing the number of variants found at each amino acid  
647 position, for each YTA classes. The TP53 domains are indicated below the heatmap  
648 to visualize the localization of TP53 variants within TP53 secondary structure.

649 Proportion of residues within each *TP53* domain for the four YTA classes (right panel).  
650 **B.** Distribution of the variants from the YTA classes within different databases:  
651 transactivation yeast assay, gnomAD database, Cosmic database, and IARC/NCI LFS  
652 dataset. Pie charts represent the number of samples with *TP53* missense variants  
653 belonging to the four YTA classes.

654

### 655 **Figure 3: Relationship between YTA classes and clinical phenotype in the Li-** 656 **Fraumeni Syndrome**

657 **A.** Distribution of *TP53* germline carriers in the IARC/NCI database into classes. Class  
658 0 includes non-missense variants (stop and frameshift). **B.** Sex distribution of  
659 individuals (F=females, M=males) for each class. **C.** Cancer accrual of individuals  
660 according to classes. The inverted Kaplan-Meier presentation corresponds to the age  
661 of onset of the first cancer in each individual. The confidence intervals at 95% are  
662 displayed on the curves, and the p-value of the Log-Rank test is indicated. **D.** Pairwise  
663 comparison of cancer accrual for each class. A multiple pairwise comparison (with  
664 Bonferroni correction) shows the significance of differences in cancer accrual between  
665 the classes (adjusted p-value). **E.** Median age of cancer accrual according to the  
666 classes. The median age is indicated as a dot, and the confidence intervals at 95% are  
667 indicated by bars aside the dot. **F.** Proportion of individuals developing more than one  
668 cancer during lifetime. For each class, the barplot displays the percentage of  
669 individuals with more than one cancer. **G.** Proportion of cancer-free individuals. For  
670 each class, the barplot shows the percentage of individuals who did not develop any  
671 cancer. **H.** Proportion of individuals with a germline variant in an established cancer  
672 predisposing gene (CPG). For each class, the barplot shows the percentage of  
673 individuals who carry a variant for a CPG other than *TP53*. **I.** Distribution of clinical  
674 classes within *TP53* classes. The proportion of individuals belonging to the following  
675 categories are displayed: Li-Fraumeni Syndrome (LFS), Li-Fraumeni like Syndrome  
676 (LFL), Chompret criteria (TP53\_Chompret), Familial History of cancer (FH), no Familial  
677 History of cancer (noFH), Other and Not Applicable (NA). **J.** Distribution of clinical  
678 phenotypes of the LFS spectrum definition within *TP53* classes. The proportion of  
679 individuals belonging to the categories LFS, attenuated LFS, and incidental LFS are  
680 displayed. Not only the P/LP *TP53* variants are included.

681

682 **Figure 4: Association of YTA classes with tumor spectrum in the Li-Fraumeni**  
683 **Syndrome. A.** Age-specific distribution of cancers (all topologies combined) for *TP53*  
684 classes. The rain-cloud plots display 1- a density plot showing distribution of age of  
685 onset for cancers, 2- a box-plot showing median age of onset as well as quartiles and  
686 outliers values, and 3- a dot-plot showing every cancer analyzed. **B.** Distribution of  
687 cancers by topology. The most frequent LFS topologies are displayed (adrenal gland,  
688 brain, bones, soft tissues, hematopoietic system and breast); all other topologies are  
689 referred as “other”. Statistical comparisons are found in Table S2. **C.** Variation of  
690 cancer topology within classes. Heatmap synthesizes cancer topology distribution from  
691 Figure 4B (normalized in row by cancer topologies).

692

693 **Figure 5: Heterogeneity of *TP53* scores within YTA classes.** Distribution of  
694 functional scorings (phenotypic selection model and relative fitness score) into all  
695 2,314 *TP53* missense variants, subdivided by YTA classes. Violin plots and dot-plots  
696 display the distribution of scores, and the median scores are indicated as white  
697 triangles.

698

699 **Figure 6: Concordance between YTA classes and ClinVar annotations. A.**  
700 Distribution of expert panel reviewed and non-expert panel reviewed *TP53* variants in  
701 the ClinVar classification. Variants from the IARC/NCI *TP53* germline database are  
702 indicated in the pie chart. The second row of pie charts represents the breakdown of  
703 expert panel reviewed variants in ClinVar categories (Pathogenic, Likely Pathogenic,  
704 Uncertain Significance, Likely Benign and Benign). Mapping of the YTA classes within  
705 each ClinVar category is displayed. The number of variants for each ClinVar category  
706 is indicated within each pie chart. **B.** Cancer accrual of each YTA class for the  
707 subcategory of expert panel reviewed *TP53* variants (top panel). The first cancer of the  
708 NCI/IARC *TP53* germline database is used to monitor cancer accrual. Confidence  
709 intervals at 95% and Log-Rank test p-value are indicated. Median age of cancer  
710 accrual according to the classes (bottom panel). The median age is indicated as a dot,  
711 and the confidence intervals at 95% are indicated by bars aside the dot. **C.** Comparison  
712 of cancer accrual for variants annotated by expert panel versus variants not annotated  
713 by expert panel (No). Left panels show cancer accrual within each YTA class. Right  
714 panels display the median and confidence intervals.

715

716 **Figure 7: Matching YTA classes to Li-Fraumeni clinical validation cohorts.** For  
717 each cohort, the patients' distribution into *TP53* classes are shown in the pie charts  
718 (left panels), as well as the cancer accrual using the age of onset for the first cancer,  
719 confidence intervals at 95% and Log-Rank p-values (right panels). **A.** Cohort 1  
720 (France) analysis. **B.** Cohort 2 (Germany) analysis. **C.** Cohort 3 (Canada) analysis.

## 721 SUPPLEMENTARY FIGURE AND TABLE LEGENDS

722  
723 **Figure S1: Yeast Transactivation Assay (YTA) -based iterative clustering of the**  
724 ***TP53* missense variants.** Transcriptional data from yeast-based assays consisting of  
725 eight measurements for 2,314 *TP53* missense variants were retrieved from Kato et al.  
726 Three layers of Ward hierarchical clustering were applied to separate variants. For  
727 each layer, heatmaps display the transactivation scores, and dendrograms represent  
728 the clusters defined by hierarchical clustering.

729  
730 **Figure S2: Hierarchy of clusters and consolidation of *TP53* variants classes. A.**  
731 Distribution of the 2,314 *TP53* missense variants in clusters. Numbers of variants are  
732 indicated in parenthesis above the cluster name. Color codes correspond to the  
733 consolidation of classes explained in Fig S2B. **B.** Consolidation of classes. Class A  
734 variants correspond to cluster 1\_1\_1; Class B variants correspond to 1\_1 cluster  
735 except class A; Class C variants correspond to cluster 1 except classes A and B; Class  
736 D variants correspond to all variants except classes A, B, and C. **C.** Distribution of  
737 transactivation scores within the consolidated classes. The heatmap displays scores  
738 for all eight promoter measurements regarding all *TP53* variants ranked by YTA  
739 classes. **D.** Distribution of transactivation classes (non-functional, partially functional,  
740 functional and supertrans) of *TP53* variants within YTA classes based on hierarchical  
741 clustering. Pareto plots display the number of *TP53* variants belonging to the  
742 transactivation classes.

743  
744 **Figure S3: Structural localization of variants from YTA classes. A.** *TP53* missense  
745 variants located on Alpha-Fold *TP53* structural modeling. The *TP53* germline variants  
746 found in the IARC/NCI LFS database are separated by YTA classes and displayed on  
747 the 3D structure. **B.** *TP53* missense variants located on crystal-based structures of the  
748 DNA binding domain (top panel) and oligomerization domain (bottom panel). *TP53*

749 germline variants found in the IARC/NCI LFS database are separated by YTA classes  
750 and displayed on the 3D structure.

751

752 **Figure S4: Mapping of YTA classes to *TP53* scores.** Pareto plots showing the  
753 distribution of functional scorings for *TP53* variants (SIFT, AGVGD, and TP53 PROF)  
754 within YTA classes.

755

756 **Figure S5: Designing the *TP53* variants class 0.** **A.** Cancer accrual for all categories  
757 of non-missense variants in individuals from the IARC/NCI *TP53* variants germline  
758 database (LFS). **B.** Comparison of median age of cancer accrual (red dots) and  
759 confidence intervals (black lines) for the categories of non-missense variants. The  
760 nonsense and frameshift variants are selected for the design of a class 0.

761

762 **Figure S6: Association of YTA classes with tumor spectrum in LFS.** Distribution  
763 of cancers by morphology subtype. Histograms displaying the percentage of all  
764 cancers of individuals from IARC/NCI *TP53* variants germline database (LFS) with  
765 specific tumor morphologies evoking LFS.

766

767 **Figure S7: YTA class specificities in the distribution of different topologies of**  
768 **cancers by age.** Rain-cloud plots showing the age distribution of the following cancer  
769 topologies: adrenal gland, bones, breast, soft tissues, brain, hematopoietic, and all  
770 other topologies (other), for the individuals of classes 0, A, B and C in the IARC/NCI  
771 *TP53* variants germline database (LFS). Class D was not considered as counts of  
772 cancers were not sufficient for analysis.

773

774 **Figure S8: Challenging YTA classes with the phenotypic selection model score**  
775 **in LFS.** **A.** Distribution of the phenotypic selection model score from Giacomelli et al.  
776 for each variant from the IARC/NCI *TP53* variants germline database. For each YTA  
777 class, dot-plots are annotated with the corresponding quartile values (25%; median;  
778 75%) to design four groups (quartile 1, quartile 2, quartile 3, and quartile 4, from lowest  
779 to highest values). **B.** Comparison of cancer accrual for individuals belonging to the  
780 four quartile groups in the same YTA class (left panels), and relationship between  
781 median age of cancer accrual and quartiles (right panel).

782



783 **Figure S9: Challenging YTA classes with the relative fitness score in LFS. A.**  
784 Distribution of the relative fitness score from Kotler et al. for each variant from the  
785 IARC/NCI *TP53* variants germline database. For each YTA class, dot-plots are  
786 annotated with the corresponding quartile values (25%; median; 75%) to design four  
787 groups (quartile 1, quartile 2, quartile 3, and quartile 4, from lowest to highest values).  
788 **B.** Comparison of cancer accrual for individuals belonging to the four quartile groups  
789 in the same YTA class (left panels), and relationship between median age of cancer  
790 accrual and quartiles (right panel).

791  
792 **Figure S10: Mapping YTA classes to the *TP53* PROF classification. A.** Distribution  
793 of YTA classes in deleterious (D) and non-deleterious (ND) classes of the *TP53*\_PROF  
794 model from Ben-Cohen et al. The number of variants from the *TP53* germline database  
795 NCI/IARC is displayed. **B.** Cancer accrual of individuals separated by YTA classes, for  
796 deleterious and for non-deleterious *TP53* variants. Log-Rank p-values are indicated.

797  
798 **Figure S11: Association of YTA classes with tumor spectrum in Li-Fraumeni**  
799 **clinical validation cohorts.** Distribution of cancers by topology. The most frequent  
800 LFS topologies are displayed (adrenal gland, brain, bones, soft tissues, hematopoietic  
801 system and breast); all other topologies are referred as “other”; cancer-free patients  
802 are indicated as “no cancer”. **A.** Cohort 1 (France) analysis. **B.** Cohort 2 (Germany)  
803 analysis. **C.** Cohort 3 (Canada) analysis.

804  
805 **Table S1: *TP53* missense variants and corresponding YTA classes.** The 2,314  
806 *TP53* missense variants are annotated with the YTA classification (classes A, B, C, D),  
807 as well as scores developed by others.

808  
809 **Table S2: Risk ratio of tumor localization for YTA classes in LFS.** Statistical  
810 significance of variation of tumor distribution (topology) for each pair-wise comparison  
811 of YTA classes.  $\chi^2$  tests are reported in the table (risk ratio between the two classes,  
812 with confidence intervals 95% and the adjusted p-value with Benjamini-Hochberg  
813 correction for multiple comparisons), for the following topologies: adrenal gland, bones,  
814 brain, breast, hematopoietic system, other, and soft tissues. Grey highlights  
815 correspond to pairwise comparison that reached adjusted p-value <0.05.

816

# Fine resolution clustering of *TP53* variants into functional classes predicts cancer risks and spectra among germline variant carriers

Emilie Montellier, PhD (1), Nathanaël Lemonnier, PhD (1), Judith Penkert, MD (2), Claire Freycon, MD (1,3,4), Sandrine Blanchet, MSc (1), Amina Amadou, PhD (1,5), Florent Chuffart, PhD (1), Nicholas Fischer, PhD (6), Maria Isabel Achatz, MD, PhD (7), Arnold Levine, PhD (8), Catherine Goudie, MD (4), David Malkin, MD, PhD (6), Gaëlle Bougeard, PhD (9), Christian Kratz, MD (2) and Pierre Hainaut, PhD (1)\*

## Affiliations:

- (1) Univ. Grenoble Alpes, Inserm 1209, CNRS 5309, Institute for Advanced Biosciences, F38000, Grenoble, France
- (2) Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
- (3) Centre Hospitalier Universitaire Grenoble Alpes, Department of Pediatrics
- (4) Department of Pediatrics, Division of Hematology-Oncology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada
- (5) Department of Prevention Cancer Environment, Centre Léon Bérard, Lyon, France
- (6) Genetics and Genome Biology Program, The Hospital for Sick Children; University of Toronto, Toronto, Ontario, Canada
- (7) Department of Oncology, Hospital Sírio-Libanês, São Paulo, Brazil
- (8) Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ
- (9) Department of Genetics, Normandy Center for Genomic and Personalized Medicine, University Hospital, Rouen, France; Normandie Univ - UniRouen, Inserm U1245, Rouen, France

## Correspondence:

\* corresponding author:



Institute for Advanced Biosciences,  
Univ. Grenoble Alpes, Inserm 1209, CNRS 5309  
Site Santé, Allée des Alpes  
F38700, La Tronche, France  
[pierre.hainaut@univ-grenoble-alpes.fr](mailto:pierre.hainaut@univ-grenoble-alpes.fr)  
Tel +33 6 20 38 05 47

## ABSTRACT

Li-Fraumeni syndrome (LFS) is a heterogeneous predisposition to a broad spectrum of cancers caused by pathogenic *TP53* germline variants. We have used a clustering approach to assign missense variants to functional classes with distinct quantitative and qualitative features based on transcriptional activity in yeast assays. Genotype-phenotype correlations were analyzed using the germline *TP53* mutation database (n = 3,446) and validated in three LFS clinical cohorts (n= 821). Carriers of class A variants recapitulated all traits of fully penetrant LFS (median age at first diagnosis = 28 years). Class B carriers showed a less penetrant form (median = 33 years, p < 0.05) dominated by adrenocortical and breast cancers. Class C or D carriers had attenuated phenotypes (median = 41 years, p < 0.001) with typical LFS cancers in C and mostly non-LFS cancers in D. This new classification provides insight into structural/functional features causing pathogenicity.

Figure 1


# Classifying *TP53* missense variants for genotype-phenotype correlations in the Li-Fraumeni Syndrome (LFS)




**Figure 2**

**A.**

**All TP53 missense variants (n=2,314)**




**B.**




# Figure 3

**A.**



**B.**





**D.**


Multiple pairwise comparison of cancer accrual

Comparison	Adjusted_P_Value	Significance
0 vs. A	1.00e+00	NS
0 vs. B	4.37e-03	**
0 vs. C	1.74e-11	***
0 vs. D	1.68e-08	***
A vs. B	2.08e-02	*
A vs. C	5.35e-11	***
A vs. D	5.54e-08	***
B vs. C	3.68e-03	**
B vs. D	3.85e-03	**
C vs. D	1.00e+00	NS


**C.**




**E.**




**F.**




**G.**




**H.**



**I.**




**J.**




**Figure 4**


**A.**




**C.**



**B.**




**Figure 5**




**Figure 6**


**A.**



**B.**





**C.**







**Figure 7**

**A. French cohort**



**B. German cohort**



**C. Canadian cohort**

